The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: John Young - Canaccord Genuity LLC - Analyst
: I'll ask one on AlphaVac and then maybe one on Auryon -- no, just AlphaVac to start. There's been the M&A in the space recently, and you have a
device has benefits that you highlighted today versus of those other on the market today.
So can you talk to us about what you're seeing for competitive switching to AlphaVac? Any color on the number of accounts that you have in that
process today that you highlighted this morning earlier? And then just plans for iteration on the device and then I have a follow up.
Question: John Young - Canaccord Genuity LLC - Analyst
: Okay. Great. Thanks, Jim. And then just on Auryon too. Any details on what the hospital outpatient mix this quarter was? I know the past was around
like 35%. Is that growing and then how should we think about ASPs as that continues to grow? Thanks again for taking our questions.
Question: John Young - Canaccord Genuity LLC - Analyst
: Great. Thanks, Stephen.
Question: Steven Lichtman - Oppenheimer & Co. Inc. - Analyst
: I guess first on ambition, I know from clinicaltrials.gov that the final readout won't be for a few years. But since it's a Phase 4, I'm wondering if there
are interim looks that you anticipate that could be released to start increasing the knowledge of Auryon's potential in BTK even before the final
data?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
APRIL 02, 2025 / 1:00PM, ANGO.OQ - AngioDynamics Inc Virtual Cardiovascular Investor Event Call
Question: Steven Lichtman - Oppenheimer & Co. Inc. - Analyst
: Okay. Got it. And then on AlphaVac, during the prepared remarks here, Steve, you mentioned surprise from some surgeons when learning about
certain functionalities that it brings. Beyond the sales force and education efforts, are there more papers and/or podium presentations at conferences
that we could see to further get the word out on AlphaVac and it's obviously a competitive market.
Question: Steven Lichtman - Oppenheimer & Co. Inc. - Analyst
: Okay. Great. Thanks again.
Question: Marie Thibault - BTIG, LLC - Analyst
: Wanted to ask one here first on Auryon, we've been seeing some increasing interest from players in the IVL market, and I just wanted to understand
how you view Auryon fitting in with other modalities for treating the peripheral arterial disease? Are there distinct advantages in terms of treating
certain types of calcium? Is there a way to maybe segment the patient population where you feel atherectomy is a better choice? Any detail on
that would be helpful.
Question: Marie Thibault - BTIG, LLC - Analyst
: Very well said. Thank you for that. A quick follow up here on AlphaVac. Any latest thoughts on where we might be with society guidelines? I know
there's some hope of formalizing this shift to mechanical thrombectomy in society guidelines. I'd love to hear your views on that. Thanks for taking
the questions.
Question: Marie Thibault - BTIG, LLC - Analyst
: It does. Thank you so much.
| 
